Programmable bio-nano-chip systems for serum CA125 quantification

Toward ovarian cancer diagnostics at the point-of-care

Archana Raamanathan, Glennon W. Simmons, Nicolaos Christodoulides, Pierre N. Floriano, Wieslaw B. Furmaga, Spencer W. Redding, Karen H. Lu, Robert C. Bast, John McDevitt

Research output: Contribution to journalArticle

Abstract

Point-of-care (POC) implementation of early detection and screening methodologies for ovarian cancer may enable improved survival rates through early intervention. Current laboratory-confined immunoanalyzers have long turnaround times and are often incompatible with multiplexing and POC implementation. Rapid, sensitive, and multiplexable POC diagnostic platforms compatible with promising early detection approaches for ovarian cancer are needed. To this end, we report the adaptation of the programmable bio-nano-chip (p-BNC), an integrated, microfluidic, and modular (programmable) platform for CA125 serum quantitation, a biomarker prominently implicated in multimodal and multimarker screening approaches. In the p-BNCs, CA125 from diseased sera (Bio) is sequestered and assessed with a fluorescence-based sandwich immunoassay, completed in the nano-nets (Nano) of sensitized agarose microbeads localized in individually addressable wells (Chip), housed in a microfluidic module, capable of integrating multiple sample, reagent and biowaste processing, and handling steps. Antibody pairs that bind to distinct epitopes on CA125 were screened. To permit efficient biomarker sequestration in a threedimensional microfluidic environment, the p-BNC operating variables (incubation times, flow rates, and reagent concentrations) were tuned to deliver optimal analytical performance under 45 minutes. With short analysis times, competitive analytical performance (inter- and intra-assay precision of 1.2% and 1.9% and limit of detection of 1.0 U/mL) was achieved on this minisensor ensemble. Furthermore, validation with sera of patients with ovarian cancer (n = 20) showed excellent correlation (R 2 = 0.97) with gold-standard ELISA. Building on the integration capabilities of novel microfluidic systems programmed for ovarian cancer, the rapid, precise, and sensitive miniaturized p-BNC system shows strong promise for ovarian cancer diagnostics.

Original languageEnglish (US)
Pages (from-to)706-716
Number of pages11
JournalCancer Prevention Research
Volume5
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Point-of-Care Systems
Microfluidics
Ovarian Neoplasms
Serum
Biomarkers
Microspheres
Immunoassay
Gold
Sepharose
Limit of Detection
Epitopes
Survival Rate
Fluorescence
Enzyme-Linked Immunosorbent Assay
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Programmable bio-nano-chip systems for serum CA125 quantification : Toward ovarian cancer diagnostics at the point-of-care. / Raamanathan, Archana; Simmons, Glennon W.; Christodoulides, Nicolaos; Floriano, Pierre N.; Furmaga, Wieslaw B.; Redding, Spencer W.; Lu, Karen H.; Bast, Robert C.; McDevitt, John.

In: Cancer Prevention Research, Vol. 5, No. 5, 05.2012, p. 706-716.

Research output: Contribution to journalArticle

Raamanathan, A, Simmons, GW, Christodoulides, N, Floriano, PN, Furmaga, WB, Redding, SW, Lu, KH, Bast, RC & McDevitt, J 2012, 'Programmable bio-nano-chip systems for serum CA125 quantification: Toward ovarian cancer diagnostics at the point-of-care', Cancer Prevention Research, vol. 5, no. 5, pp. 706-716. https://doi.org/10.1158/1940-6207.CAPR-11-0508
Raamanathan, Archana ; Simmons, Glennon W. ; Christodoulides, Nicolaos ; Floriano, Pierre N. ; Furmaga, Wieslaw B. ; Redding, Spencer W. ; Lu, Karen H. ; Bast, Robert C. ; McDevitt, John. / Programmable bio-nano-chip systems for serum CA125 quantification : Toward ovarian cancer diagnostics at the point-of-care. In: Cancer Prevention Research. 2012 ; Vol. 5, No. 5. pp. 706-716.
@article{e78e640e74394553aae184a1c80335b4,
title = "Programmable bio-nano-chip systems for serum CA125 quantification: Toward ovarian cancer diagnostics at the point-of-care",
abstract = "Point-of-care (POC) implementation of early detection and screening methodologies for ovarian cancer may enable improved survival rates through early intervention. Current laboratory-confined immunoanalyzers have long turnaround times and are often incompatible with multiplexing and POC implementation. Rapid, sensitive, and multiplexable POC diagnostic platforms compatible with promising early detection approaches for ovarian cancer are needed. To this end, we report the adaptation of the programmable bio-nano-chip (p-BNC), an integrated, microfluidic, and modular (programmable) platform for CA125 serum quantitation, a biomarker prominently implicated in multimodal and multimarker screening approaches. In the p-BNCs, CA125 from diseased sera (Bio) is sequestered and assessed with a fluorescence-based sandwich immunoassay, completed in the nano-nets (Nano) of sensitized agarose microbeads localized in individually addressable wells (Chip), housed in a microfluidic module, capable of integrating multiple sample, reagent and biowaste processing, and handling steps. Antibody pairs that bind to distinct epitopes on CA125 were screened. To permit efficient biomarker sequestration in a threedimensional microfluidic environment, the p-BNC operating variables (incubation times, flow rates, and reagent concentrations) were tuned to deliver optimal analytical performance under 45 minutes. With short analysis times, competitive analytical performance (inter- and intra-assay precision of 1.2{\%} and 1.9{\%} and limit of detection of 1.0 U/mL) was achieved on this minisensor ensemble. Furthermore, validation with sera of patients with ovarian cancer (n = 20) showed excellent correlation (R 2 = 0.97) with gold-standard ELISA. Building on the integration capabilities of novel microfluidic systems programmed for ovarian cancer, the rapid, precise, and sensitive miniaturized p-BNC system shows strong promise for ovarian cancer diagnostics.",
author = "Archana Raamanathan and Simmons, {Glennon W.} and Nicolaos Christodoulides and Floriano, {Pierre N.} and Furmaga, {Wieslaw B.} and Redding, {Spencer W.} and Lu, {Karen H.} and Bast, {Robert C.} and John McDevitt",
year = "2012",
month = "5",
doi = "10.1158/1940-6207.CAPR-11-0508",
language = "English (US)",
volume = "5",
pages = "706--716",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Programmable bio-nano-chip systems for serum CA125 quantification

T2 - Toward ovarian cancer diagnostics at the point-of-care

AU - Raamanathan, Archana

AU - Simmons, Glennon W.

AU - Christodoulides, Nicolaos

AU - Floriano, Pierre N.

AU - Furmaga, Wieslaw B.

AU - Redding, Spencer W.

AU - Lu, Karen H.

AU - Bast, Robert C.

AU - McDevitt, John

PY - 2012/5

Y1 - 2012/5

N2 - Point-of-care (POC) implementation of early detection and screening methodologies for ovarian cancer may enable improved survival rates through early intervention. Current laboratory-confined immunoanalyzers have long turnaround times and are often incompatible with multiplexing and POC implementation. Rapid, sensitive, and multiplexable POC diagnostic platforms compatible with promising early detection approaches for ovarian cancer are needed. To this end, we report the adaptation of the programmable bio-nano-chip (p-BNC), an integrated, microfluidic, and modular (programmable) platform for CA125 serum quantitation, a biomarker prominently implicated in multimodal and multimarker screening approaches. In the p-BNCs, CA125 from diseased sera (Bio) is sequestered and assessed with a fluorescence-based sandwich immunoassay, completed in the nano-nets (Nano) of sensitized agarose microbeads localized in individually addressable wells (Chip), housed in a microfluidic module, capable of integrating multiple sample, reagent and biowaste processing, and handling steps. Antibody pairs that bind to distinct epitopes on CA125 were screened. To permit efficient biomarker sequestration in a threedimensional microfluidic environment, the p-BNC operating variables (incubation times, flow rates, and reagent concentrations) were tuned to deliver optimal analytical performance under 45 minutes. With short analysis times, competitive analytical performance (inter- and intra-assay precision of 1.2% and 1.9% and limit of detection of 1.0 U/mL) was achieved on this minisensor ensemble. Furthermore, validation with sera of patients with ovarian cancer (n = 20) showed excellent correlation (R 2 = 0.97) with gold-standard ELISA. Building on the integration capabilities of novel microfluidic systems programmed for ovarian cancer, the rapid, precise, and sensitive miniaturized p-BNC system shows strong promise for ovarian cancer diagnostics.

AB - Point-of-care (POC) implementation of early detection and screening methodologies for ovarian cancer may enable improved survival rates through early intervention. Current laboratory-confined immunoanalyzers have long turnaround times and are often incompatible with multiplexing and POC implementation. Rapid, sensitive, and multiplexable POC diagnostic platforms compatible with promising early detection approaches for ovarian cancer are needed. To this end, we report the adaptation of the programmable bio-nano-chip (p-BNC), an integrated, microfluidic, and modular (programmable) platform for CA125 serum quantitation, a biomarker prominently implicated in multimodal and multimarker screening approaches. In the p-BNCs, CA125 from diseased sera (Bio) is sequestered and assessed with a fluorescence-based sandwich immunoassay, completed in the nano-nets (Nano) of sensitized agarose microbeads localized in individually addressable wells (Chip), housed in a microfluidic module, capable of integrating multiple sample, reagent and biowaste processing, and handling steps. Antibody pairs that bind to distinct epitopes on CA125 were screened. To permit efficient biomarker sequestration in a threedimensional microfluidic environment, the p-BNC operating variables (incubation times, flow rates, and reagent concentrations) were tuned to deliver optimal analytical performance under 45 minutes. With short analysis times, competitive analytical performance (inter- and intra-assay precision of 1.2% and 1.9% and limit of detection of 1.0 U/mL) was achieved on this minisensor ensemble. Furthermore, validation with sera of patients with ovarian cancer (n = 20) showed excellent correlation (R 2 = 0.97) with gold-standard ELISA. Building on the integration capabilities of novel microfluidic systems programmed for ovarian cancer, the rapid, precise, and sensitive miniaturized p-BNC system shows strong promise for ovarian cancer diagnostics.

UR - http://www.scopus.com/inward/record.url?scp=84866142743&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866142743&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-11-0508

DO - 10.1158/1940-6207.CAPR-11-0508

M3 - Article

VL - 5

SP - 706

EP - 716

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 5

ER -